Prostate Cancer | Pharmacor | G7 | 2015

Last Updated 22 October 2015
The drug treatment of prostate cancer has evolved rapidly over the last few years—the metastatic castrate-resistant prostate cancer (mCRPC) setting has become crowded and competitive following the launch of five efficacious therapies since 2010, and the hormonal agents Zytiga (Johnson & Johnson/Janssen Biotech/Janssen-Cilag/AstraZeneca’s abiraterone) and Xtandi (Medivation/Astellas Pharma’s enzalutamide) compete fiercely in this setting. The prostate cancer drug development pipeline is dynamic, and agents in late-phase development span a wide range of drug classes. The expected launch of several emerging therapies for prostate cancer over 2014-2024 will heighten the competition, and it will be imperative for current and emerging therapies to differentiate and position themselves to maximize clinical and commercial success.

Login to access report